Antibe Therapeutics Inc. Announces Annual Compensation Changes And Grant Of Stock Options

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE) is pleased to announce that following the annual review by the Compensation Committee of the performance of the Corporation and the compensation practices of its peer companies, all personnel including Officers have been granted a 5% pay increase, and that today the Corporation has granted its management team options to purchase a total of 1,000,000 common shares of Antibe pursuant to the Corporation’s stock option plan. Each option bears an exercise price of $0.66, being the closing price of Antibe shares on March 3, 2014, and an expiry date of March 4, 2024.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC